Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ADAPT-C
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
- NCT04585490 ↗
- Recruiting
- Stanford University
- Focused
We haven't built an HCP commentary report on ADAPT-C yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ADAPT-C so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- ADAPT-C: Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non Small Cell Lung Cancer; NSCLC, Stage III; Nsclc
- Interventions
- Durvalumab; Carboplatin; Pemetrexed; Paclitaxel; Cisplatin; AVENIO ctDNA Surveillance Kit; Tremelimumab
- Arms
- Cohort 1 minimal residual disease positive (MRD+) · Experimental
- Cohort 2 minimal residual disease negative (MRD ) · Experimental
- Enrollment
- 48 (estimated)
- Primary outcomes
- Change in ctDNA Level Following Chemotherapy
- Sponsor
- Stanford University with AstraZeneca
- Start
- Aug 25, 2021
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04585490 · updated Sep 30, 2026